May 5, 2021
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
TYPE OF SARCOMA: Uterine Leiomyosarcoma
DRUG: Gemcitabine and Docetaxel
ACCRUAL STATUS: Completed
OVERALL STUDY PRINCIPAL INVESTIGATOR:
Martee L. Hensley, MD
Memorial Sloan Kettering Cancer Center
CLINICALTRIALS.GOV IDENTIFIER: NCT00282087
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study or to contact the study research staff: